

Vers 4.5	ion	Revision Date: 06.04.2024		S Number: 107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
SEC	TION 1 Product	IDENTIFICATION	:	Orbifloxacin / Pos	saconazole / Mometasone Formulation
	Manufa	cturer or supplier's d	letai	ls	
	Compa	ny	:	Intervet Australia	Pty Limited (trading as MSD Animal Health)
	Addres	5	:	91-105 Harpin St Bendigo 3550, V	
	Telepho	one	:	1 800 033 461	
	Emerge	ency telephone number	:	Poisons Informat	ion Centre: Phone 13 11 26
	E-mail a	address	:	EHSDATASTEW	ARD@msd.com
	Recom	mended use of the ch	nemi	ical and restrictio	ons on use
		mended use ions on use	:	Veterinary produc Not applicable	ct

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification Serious eye damage/eye irri- tation	:	Category 2B
GHS label elements Hazard pictograms Signal word	:	None Warning
Hazard statements	:	H320 Causes eye irritation.
Precautionary statements	:	Prevention: P264 Wash skin thoroughly after handling.
		Response: P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 If eye irritation persists: Get medical advice/ at- tention.

Other hazards which do not result in classification None known.



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 60 -<= 100
Orbifloxacin	113617-63-3	< 3
Posaconazole	171228-49-2	< 1
Mometasone	83919-23-7	< 0.3

SECTION 4. FIRST AID MEASURES

General advice	:	vice immediately. When symptoms persist or in all cases of doubt seek medical
If inhaled	:	advice. If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes eye irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.



Versio 4.5	n Revision Date: 06.04.2024		9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
	azardous combustion prod-	:	Carbon oxides	
_	cts pecific extinguishing meth- ds	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers.
fo	pecial protective equipment r firefighters azchem Code		so. Evacuate area. In the event of fire	ged containers from fire area if it is safe to do e, wear self-contained breathing apparatus. rective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures		e Engineering measures under EXPOSURE DNTROLS/PERSONAL PROTECTION section.
Local/Total ventilation		sufficient ventilation is unavailable, use with local exhaust ntilation.
Advice on safe handling	Do	not get on skin or clothing. not breathe vapours or spray mist. not swallow.



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
Hygie	ene measures	 Handle in accorpractice, base sessment Keep container Take care to penvironment. If exposure to flushing system place. When using de Wash contamin The effective of engineering corporate de industrial hygic 	eyes. roughly after handling. ordance with good industrial hygiene and safety d on the results of the workplace exposure as- er tightly closed. orevent spills, waste and minimize release to the chemical is likely during typical use, provide eye ms and safety showers close to the working o not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, ene monitoring, medical surveillance and the strative controls.
Cond	litions for safe storage	Keep tightly cl	
Mate	rials to avoid		dance with the particular national regulations. vith the following product types: ng agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
		exposure)	concentration	
White mineral oil (petroleum)	8042-47-5	TWA (Mist)	5 mg/m3	AU OEL
		TWA (Inhal-	5 mg/m3	ACGIH
		able particu-		
		late matter)		
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Posaconazole	171228-49-2	TWA	300 µg/m3 (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	ation: Skin		
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety



Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipme	ent	
Respiratory protection	S	f adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.
Filter type Hand protection	: (Combined particulates and organic vapour type
Material	: (Chemical-resistant gloves
Remarks Eye protection	: \ r k	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	r t	Work uniform or laboratory coat. Additional body garments should be used based upon the cask being performed (e.g., sleevelets, apron, gauntlets, dis- cosable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available



Orbifloxacin / Posaconazole / Mometasone Formulation

Versio 4.5	'n	Revision Date: 06.04.2024		S Number: 9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
Va	apour	pressure	:	No data available	9
R	elative	e vapour density	:	No data available	9
R	elative	e density	:	No data available	9
D	ensity		:	No data available	9
So	olubili Wate	ty(ies) er solubility	:	No data available	9
		n coefficient: n-	:	Not applicable	
		/water hition temperature	:	No data available	9
D	ecom	position temperature	:	No data available	9
Vi	iscosit Visc	y osity, kinematic	:	No data available	9
E	xplosi	ve properties	:	Not explosive	
0	xidizir	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	article article	characteristics size	:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

:	Not classified as a reactivity hazard.
:	Stable under normal conditions.
:	Can react with strong oxidizing agents.
:	None known.
:	Oxidizing agents
:	No hazardous decomposition products are known.
	:

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes

: Inhalation



ersion 5	Revision Date: 06.04.2024		9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016	
			Skin contact Ingestion Eye contact		
	e toxicity				
	lassified based on availa	ble	information.		
<u>Produ</u> Acute	u <u>ct:</u> e oral toxicity	:	LD50 (Rat): > 2,0 Remarks: No sigr No mortality obse	hificant adverse effects were reported	
Acute	e dermal toxicity	:	LD50 (Rat): > 2,0 Remarks: No sigr	00 mg/kg ificant adverse effects were reported	
<u>Com</u> r	oonents:				
White	e mineral oil (petroleum	ו):			
Acute	oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg	
Acute	inhalation toxicity	:	LC50 (Rat): > 5 m Exposure time: 4 Test atmosphere: Assessment: The tion toxicity	ĥ	
Acute	Acute dermal toxicity		LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute derma toxicity		
Orbif	loxacin:				
Acute	e oral toxicity	:	LD50 (Rat): > 3,0 Remarks: No mor	00 mg/kg tality observed at this dose.	
			LD50 (Mouse): > Remarks: No mor	2,000 mg/kg tality observed at this dose.	
			LD50 (Dog): > 60 Symptoms: Vomit Remarks: No mor		
Acute	inhalation toxicity	: Remarks:		a available	
Acute	e dermal toxicity	:	Remarks: No data	a available	
	e toxicity (other routes of nistration)	:	LD50 (Rat): > 200 Application Route		
			LD50 (Mouse): 50 Application Route		



rsion	Revision Date: 06.04.2024		9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
			LD50 (Rat): 233 n Application Route	
			LD50 (Mouse): 25 Application Route	
Posa	conazole:			
Acute	oral toxicity	:	LD50 (Rat): > 5,0	000 mg/kg
			LD50 (Mouse): >	3,000 mg/kg
Acute	e dermal toxicity	:	LD50 (Rat): > 2,0	000 mg/kg
Mome	etasone:			
Acute	oral toxicity	:	LD50 (Rat): > 2,0	000 mg/kg
			LD50 (Mouse): >	2,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 3.3 Exposure time: 4 Test atmosphere	h : dust/mist
			LC50 (Mouse): > Exposure time: 4 Test atmosphere	h
	e toxicity (other routes of histration)	:	LD50 (Rat): 300 n Application Route Symptoms: Breat	e: Subcutaneous
Skin	corrosion/irritation			
Not cl	assified based on availa	ble	information.	
<u>Produ</u> Speci Resul	es	:	Rabbit Mild skin irritation	
		•		I
Comp	oonents:			
	e mineral oil (petroleum):	D 11 %	
Speci Resul		:	Rabbit No skin irritation	
	loxacin:			
Orbif				
Orbif Speci	es	:	Rabbit	



Orbifloxacin / Posaconazole / Mometasone Formulation

Vers 4.5	sion	Revision Date: 06.04.2024	SDS Number: 439107-00019		Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
	Result		:	No skin irritation	
	Posaco	nazole:			
	Species	5	:	Rabbit	
	Result		:	No skin irritation	
	Mometa	asone:			
	Species	5	:	Rabbit	
	Result		:	No skin irritation	
	Serious	s eye damage/eye irri	tati	on	
		eye irritation.			
	Produc	<u>t:</u>			
	Species	i	:	Rabbit	
	Result		:	Mild eye irritation	
	<u>Compo</u>	nents:			
	White n	nineral oil (petroleum	ו):		
	Species Result	;	:	Rabbit No eye irritation	
	Orbiflo	xacin:			
	Species	;	:	Rabbit	
	Result		:	Mild eye irritation	
	Method		:	Draize Test	
	Posaco	nazole:			
	Species	5	:	Rabbit	
	Result		:	Mild eye irritation	
	Mometa	asone:			
	Species	;	:	Rabbit	
	Result		:	No eye irritation	
	Respira	atory or skin sensitis	atic	n	
	Skin se	nsitisation			
	Not clas	sified based on availa	ble	information.	
	-	atory sensitisation	ble	information	
	Produc Test Ty		:	Magnusson-Kligm	aan-Test
	ICOLIV	he	•	maynussun=migh	

Test Type

: Magnusson-Kligman-Test



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016	
Expo Resu	sure routes It	: Dermal : Not a skin se	ensitizer.	
Com	ponents:			
White	e mineral oil (petrole	eum):		
Test		; Buehler Tes	t	
	sure routes	: Skin contact		
Spec Resu		: Guinea pig : negative		
Orbif	loxacin:			
Test		: Maximisation	n Test	
	sure routes	: Dermal		
Spec Resu		: Guinea pig : Not a skin se	ensitizer.	
Posa	conazole:			
Test			Kligman-Test	
Expo Speci	sure routes	: Skin contact		
Resu		: Guinea pig : negative		
Mom	etasone:			
Test		: Maximisation	n Test	
Expo Speci	sure routes	: Dermal : Guinea pig		
	ssment		use skin sensitisation.	
Resu		: negative		
Rema	arks		of a test on guinea pigs showed this substance to kin sensitiser.	
Chro	nic toxicity			
	n cell mutagenicity lassified based on ava	ailable information.		
Com	ponents:			
White	e mineral oil (petrole	eum):		
Geno	toxicity in vitro	: Test Type: I Result: nega	n vitro mammalian cell gene mutation test tive	
Geno	otoxicity in vivo	cytogenetic Species: Mo Application F	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474	



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016		
		Result: negativ Remarks: Bas	ve ed on data from similar materials		
Orbif	loxacin:				
Geno	toxicity in vitro	: Test Type: Ba Result: equivo	cterial reverse mutation assay (AMES) ocal		
		Test Type: Mo Result: positiv	ouse Lymphoma e		
			romosomal aberration Human lymphocytes e		
Geno	toxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative			
		Test Type: uns Species: Rat Cell type: Live Application Ro Result: negativ	oute: Oral		
	i cell mutagenicity - ssment	: Weight of evid cell mutagen.	lence does not support classification as a germ		
Posa	conazole:				
Geno	toxicity in vitro	: Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) ve		
		Test Type: Ch Result: negativ	romosomal aberration ve		
Geno	toxicity in vivo	Species: Mous Cell type: Bon	e marrow bute: Intravenous		
Mom	etasone:				
Geno	toxicity in vitro	: Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) ve		
			romosomal aberration Chinese hamster lung cells ve		



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		Test system: Result: positi	louse Lymphoma
Geno	otoxicity in vivo	-	licronucleus test use Route: Oral
		Test Type: C Species: Rat Cell type: Bo Result: nega	ne marrow
		Test Type: u Species: Rat Cell type: Liv Result: nega	ver cells
	n cell mutagenicity - essment	: Weight of ev cell mutagen	idence does not support classification as a germ
	inogenicity classified based on avail	able information.	
<u>Com</u>	ponents:		
Whit	e mineral oil (petroleur	m):	
	ication Route	: Rat : Ingestion : 24 Months : negative	
Orbi	floxacin:		
Spec Appli	cies ication Route osure time EL	: Rat : Oral : 2 Years : 200 mg/kg be : negative	ody weight
	ication Route osure time EL	: Mouse : Oral : 2 Years : 200 mg/kg b : negative	ody weight



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
Spec Applie Expo Resu Rema Spec Applie	cation Route sure time It arks	: Rat : oral (feed) : 2 Years : positive : The mechani : Mouse : Oral : 2 Years	sm or mode of action is not relevant in humans.
Resu Rema	lt	: positive : The mechani	sm or mode of action is not relevant in humans.
Spec Applie Expo Dose Resu Spec Applie Expo Dose Resu	cation Route sure time It ies cation Route sure time It	 Rat Inhalation 2 Years 0.067 mg/kg negative Mouse Inhalation 19 Months 0.160 mg/kg negative 	
•	oductive toxicity lassified based on avai	lable information.	
	<u>ponents:</u> e mineral oil (petroleu	m).	
	ts on fertility	: Test Type: O Species: Rat	ne-generation reproduction toxicity study oute: Skin contact ive
Effec ment	ts on foetal develop-	Species: Rat	nbryo-foetal development oute: Ingestion ive
	loxacin: ts on fertility	Species: Rat Application R General Toxic	vo-generation reproduction toxicity study oute: Oral city - Parent: NOAEL: 50 mg/kg body weight onic Development: NOAEL: 50 mg/kg body



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		Result: No ac	lverse effects
Effec men	cts on foetal develop- t	Species: Rat Application R Embryo-foeta Result: No te	I toxicity: LOAEL: 333 mg/kg body weight ratogenic effects, Embryotoxic effects and ad- on the offspring were detected only at high ma-
		Species: Rab Application R General Toxi Embryo-foeta Result: No ef toxic effects a	oute: Oral city Maternal: NOAEL: 20 mg/kg body weight Il toxicity: NOAEL: 60 mg/kg body weight fects on early embryonic development, Embryo- and adverse effects on the offspring were detect- h maternally toxic doses, Reduced maternal
	roductive toxicity - As- ment	: Some eviden animal exper	ce of adverse effects on development, based on ments.
Posa	aconazole:		
Effec	cts on fertility	Species: Rat General Toxi	city - Parent: NOAEL: 180 mg/kg body weight lo effects on mating performance
		Species: Rat General Toxi	city - Parent: NOAEL: 45 mg/kg body weight lo effects on mating performance
Effeo men	cts on foetal develop- t	Species: Rat Application R Development	
		Test Type: E	mbryo-foetal development



Versi 4.5	ion	Revision Date: 06.04.2024	-	OS Number: 9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
				Species: Rabbit, Developmental T Result: Fetotoxici	oxicity: LOAEL: 40 mg/kg body weight
	Reprod sessme	uctive toxicity - As- ent	:	Some evidence o animal experimer	f adverse effects on development, based on nts.
	Momet	25000.			
		on fertility	:	Symptoms: Redu weight	
	Effects ment	on foetal develop-	:	Species: Mouse Application Route Embryo-foetal tox	vo-foetal development e: Subcutaneous kicity: LOAEL: 0.06 mg/kg body weight xic effects., Teratogenicity and developmen-
				Species: Rat Application Route	ticity: LOAEL: 0.3 mg/kg body weight
				Species: Rabbit Application Route Embryo-foetal tox	vo-foetal development e: Dermal cicity: LOAEL: 0.15 mg/kg body weight petal toxicity, Malformations were observed.
				Species: Rat Application Route	ticity: LOAEL: 0.15 mg/kg body weight
				Species: Rabbit Application Route Embryo-foetal tox	vo-foetal development e: Oral kicity: LOAEL: 0.7 mg/kg body weight betal toxicity, Malformations were observed.
	Reprod sessme	uctive toxicity - As- ent	:	animal experimer	adverse effects on development, based on ats., Some evidence of adverse effects on ad fertility, based on animal experiments.



Versi 4.5	ion	Revision Date: 06.04.2024		DS Number: 9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		- single exposure ssified based on ava	ilable	information	
		onents:	labio		
	Mome t Remar	t asone: ks	:	Based on availa	ble data, the classification criteria are not met.
		- repeated exposure ssified based on ava		information.	
	Compo	onents:			
		onazole:			
		ure routes Organs	:	Ingestion Adrenal gland, I organs, Nervou	Bone marrow, Kidney, Liver, Reproductive s system
	Assess	sment	:	Causes damage exposure.	e to organs through prolonged or repeated
	Mome	asone:			
-		ure routes Organs sment	:		/mist/fume) , Liver, Kidney, Skin age to organs through prolonged or repeated
	Repea	ted dose toxicity			
	Compo	onents:			
,	White	mineral oil (petroleu	ım):		
	Specie LOAEL		:	Rat 160 mg/kg	
		- ation Route	:	Ingestion	
	Exposi	ure time	:	90 Days	
	Specie		:	Rat	
		- ation Route	:	>= 1 mg/l inhalation (dust/	/mist/fume)
	Exposi	ure time	:	4 Weeks	
	Method	Ł	:	OECD Test Gui	deline 412
	Orbiflo	oxacin:			
	Specie		:	Rat	
	NOAEI LOAEL		:	20 mg/kg 80 mg/kg	
		- ation Route	:	Oral	



/ersion I.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
•	sure time	: 3 Months	idaay aalaan
Targe	et Organs	: Testis, Liver, K	idney, spieen
Speci		: Mouse	
NOAE		: 80 mg/kg	
LOAE		: 250 mg/kg	
	cation Route sure time	: Oral : 3 Months	
Expor			
Speci		: Juvenile dog	
NOAE		: 50 mg/kg	
LOAE	cation Route	: 250 mg/kg : Oral	
	sure time	: 14 Days	
	et Organs	: Heart, Bone	
Symp	toms	: Gastrointestina	Il disturbance
Rema	arks	: mortality obser	ved
Speci	es	: Juvenile dog	
NOAE		: 2 mg/kg	
LOAE		: 3 mg/kg	
	cation Route	: Oral	
	sure time	: 90 Days : Bone	
Rema	et Organs arks		adverse effects were reported
Speci	es	: Dog	
NOAE		: 37.5 mg/kg	
Applic	cation Route	: Oral	
Expos	sure time	: 30 Days	
Speci	es	: Cat	
NOAE		: 7.5 mg/kg	
LOAE		: 22.5 mg/kg	
	cation Route	: Oral	
Expos Symp	sure time	: 1 Months : Gastrointestina	al disturbance
Symp	toms	. Gastronnesting	a disturbance
Posa	conazole:		
Speci	es	: Rat, female	
LÕAE		: 5 mg/kg	
	cation Route	: Oral	
	sure time	: 6 Months	Lunga Haart Liver anlean Kidney Over
rarge	et Organs	. Aurenai giand,	Lungs, Heart, Liver, spleen, Kidney, Ovary
Speci		: Dog	
LOAE		: 3 mg/kg	
	cation Route	: Oral	
	sure time et Organs	: 392 Days · Lungs Liver B	rain, small intestine, Adrenal gland, Spinal
raiye	- Organo		ani, ontai inteotine, Aurenai gianu, opinai



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		cord, lymphoic	l tissue
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrow,	Adrenal gland, Lymph nodes, Blood
Expo			, Bone marrow, Kidney, Nervous system, s gland, Testis, lymphoid tissue
Expo		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastroi	ntestinal tract, spleen
Expo		: Monkey : 8 mg/kg : Intravenous : 1 Months : Cardio-vascula	ar system, Lungs, Adrenal gland, Blood
Mom	etasone:		
Expo	EL	: Rat : 0.005 mg/kg : 0.3 mg/kg : Oral : 30 d : Lymph nodes,	Liver, Adrenal gland, Skin, thymus gland
Expo		: Dog : 0.5 mg/kg : Oral : 30 d : Lymph nodes,	Liver, Adrenal gland, Skin, thymus gland
Expo		: Rat : 0.00013 mg/l : inhalation (dus : 90 d : Adrenal gland, Kidney, Liver,	Lungs, Lymph nodes, spleen, Bone marrow,
Spec NOAI		: Dog : 0.0005 mg/l	

Version



Date of last issue: 30.09.2023

Orbifloxacin / Posaconazole / Mometasone Formulation

Revision Date: SDS Number:

ersion .5	Revision Date: 06.04.2024	SDS Ni 439107		Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
Expo	cation Route sure time et Organs	: 90 d : Adr	enal gland, l	/mist/fume) Lungs, Lymph nodes, spleen, Bone marrow, gland, Liver
Aspi	ration toxicity			
	lassified based on av	ailable infor	mation.	
<u>Com</u>	ponents:			
-	etasone: pplicable			
Expe	rience with human e	exposure		
<u>Com</u>	ponents:			
Orbif	loxacin:			
Inges	tion	dist	urbance, live	tral nervous system effects, Gastrointestinal er function change, anaphylaxis, Rash cause photosensitisation.
Posa	conazole:			
Inges	tion	effe		ıgh, Headache, Nausea, Vomiting, Fever, Liv ruritis, Diarrhoea, hypertension, neutropenia, lance
Mom	etasone:			
Inhala	ation	pira	tory tract inf	rgic rhinitis, Headache, pharyngitis, upper res ection, sinusitis, oral candidiasis, Back pain, I pain, immune system effects, indigestion
Skin	contact			matitis, Itching
Furth	ner information			
Com	ponents:			
Mom Rema	etasone: arks	: Der	mal absorpt	ion possible
ECTION	12. ECOLOGICAL II	NFORMATI	ON	
Ecot	oxicity			
	ponents:			
	e mineral oil (petrole	nim).		
	ity to fish	: LC5 Exp	osure time:	nchus mykiss (rainbow trout)): > 100 mg/l 96 h Test Guideline 203



Vers 4.5	ion	Revision Date: 06.04.2024		9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity plants	to algae/aquatic	:	NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
	Toxicity icity)	to fish (Chronic tox-	:	NOEC (Oncorhyn Exposure time: 28	chus mykiss (rainbow trout)): 1,000 mg/l 3 d
		to daphnia and other invertebrates (Chron- ty)	:	NOEC (Daphnia r Exposure time: 21	nagna (Water flea)): 1,000 mg/l d
	Posaco Toxicity	onazole: to fish	:	Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity plants	to algae/aquatic	:	EC50 (Pseudokiro 0.509 mg/l Exposure time: 72 Method: OECD To	
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
	Toxicity icity)	to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 33 Method: OECD Te	
		to daphnia and other invertebrates (Chron- ty)	:	Exposure time: 21 Method: OECD Te	
	Toxicity	to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition



Versio 4.5		Revision Date: 06.04.2024		95 Number: 9107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
	lometa oxicity		:	Exposure time: 96	ryllina (Silverside)): 0.11 mg/l 5 h city at the limit of solubility
				Exposure time: 7	n variegatus (sheepshead minnow)): > 5 mg/l d city at the limit of solubility
		to daphnia and other invertebrates	:	Exposure time: 48 Method: OECD Te	
				EC50 (Americamy Exposure time: 96 Method: US-EPA Remarks: No toxic	Sh'
	oxicity lants	to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD Te	
	oxicity city)	to fish (Chronic tox-	:	NOEC (Pimephale mg/l Exposure time: 32 Method: OECD Te	
a		to daphnia and other invertebrates (Chron- y)	:	Exposure time: 21 Method: OECD Te	
T	oxicity	to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxid	h ation inhibition
				NOEC: 1,000 mg/ Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxic	h ation inhibition



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

Persistence and degradability

Components:		
White mineral oil (petroleum)):	
Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d
Posaconazole:		
Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water	:	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111
Mometasone:		
Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	:	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111
Bioaccumulative potential		
Components:		
Posaconazole:		
Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
Partition coefficient: n- octanol/water	:	log Pow: 4.15
Mometasone:		
Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305
Partition coefficient: n- octanol/water	:	log Pow: 4.68



4.5 06.04.2024 439107-00019 Date of first issue: 06.01.2016	Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
	4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

Mobility in soil

Components:

Posaconazole:

Distribution among environ- mental compartments	:	log Koc: 5.52
Mometasone:		
Distribution among environ- mental compartments	:	log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
		N.O.S.
		(Mometasone, Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes
IATA-DGR		
UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passen- ger aircraft)	:	964
Environmentally hazardous	:	yes
IMDG-Code		



Version 4.5	Revision Date: 06.04.2024	SDS Number: 439107-00019	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016	

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
	N.O.S.
	(Mometasone, Posaconazole)
Class	: 9
Packing group	: 111
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

ADG		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
		(Mometasone, Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	9
Hazchem Code	:	•3Z
Environmentally hazardous	:	yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mix-
ture

Therapeutic Goods (Poisons	:	Schedule 5 (Please use the original publication to check for
Standard) Instrument		specific uses, specific conditions or threshold limits that might
		apply for this chemical)

Prohibition/Licensing Requirements

: There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS	:	not determined

DSL : not determined



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

IECSC

: not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION

Further information				
Revision Date Sources of key data used to compile the Safety Data Sheet	:	06.04.2024 Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/		
Date format	:	dd.mm.yyyy		
Full text of other abbreviations				
ACGIH AU OEL	:	USA. ACGIH Threshold Limit Values (TLV) Australia. Workplace Exposure Standards for Airborne Con- taminants.		
ACGIH / TWA AU OEL / TWA	:	8-hour, time-weighted average Exposure standard - time weighted average		

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response: ELx - Loading rate associated with x% response: EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.5	06.04.2024	439107-00019	Date of first issue: 06.01.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN